Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Master Regulator
100%
Hepatocellular Carcinoma
100%
Tumor Cells
88%
Tumor
44%
Combination Therapy
33%
Tumor Microenvironment
33%
Tyrosine Kinase Inhibitor
22%
Cell-intrinsic
22%
CRISPR Activation
22%
CRISPR Interference (CRISPRi)
22%
Human Hepatocellular Carcinoma
11%
Moderating Effect
11%
Monotherapy
11%
Signaling Cascades
11%
Mutational Profile
11%
Computational Biology
11%
Major Challenges
11%
Altered Metabolism
11%
Driver mutations
11%
Cell-type Specificity
11%
Synergize
11%
Transcriptional Regulatory
11%
Effective Treatment
11%
Intrinsic Function
11%
Effects on Survival
11%
Single-cell RNA Sequencing (scRNA-seq)
11%
In Vivo Screen
11%
Therapeutic Concepts
11%
Test Combination
11%
Transcriptional Regulation
11%
VEGF Inhibitors
11%
Atezolizumab
11%
Human Cohort
11%
In Vivo CRISPR
11%
Multidisciplinary Team
11%
Patient Survival
11%
FDA Approval
11%
Tumor Microenvironment Targeting
11%
Therapeutic Gap
11%
Cell-based
11%
Lenvatinib
11%
Human-related
11%
Synergistic Interaction
11%
Cancer Transcriptome
11%
Tumor Growth
11%
High Genetic Diversity
11%
Targeted Therapy
11%
Tumor Cell Targeting
11%
Immune Checkpoint Therapy
11%
Growth Factor Signaling
11%
Regulatory Landscape
11%
Intrinsic Vulnerability
11%
Biochemistry, Genetics and Molecular Biology
CRISPR Activation
100%
Tyrosine Kinase Inhibitor
100%
CRISPR Interference
100%
Immune Checkpoint Inhibitor
50%
Targeted Therapy
50%
Growth Factor Signaling
50%
Tumor Progression
50%
RNA Sequencing
50%
Transcriptome
50%
CRISPR
50%
Metabolic Pathway
50%
Cell Specificity
50%
Genetic Divergence
50%
Vascular Endothelial Growth Factor
50%
Bevacizumab
50%